BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11035093)

  • 1. Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1.
    Friedman HM; Wang L; Pangburn MK; Lambris JD; Lubinski J
    J Immunol; 2000 Oct; 165(8):4528-36. PubMed ID: 11035093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody.
    Hook LM; Lubinski JM; Jiang M; Pangburn MK; Friedman HM
    J Virol; 2006 Apr; 80(8):4038-46. PubMed ID: 16571820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
    Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
    J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune evasion properties of herpes simplex virus type 1 glycoprotein gC.
    Friedman HM; Wang L; Fishman NO; Lambris JD; Eisenberg RJ; Cohen GH; Lubinski J
    J Virol; 1996 Jul; 70(7):4253-60. PubMed ID: 8676446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycoprotein C of Herpes Simplex Virus 1 Shields Glycoprotein B from Antibody Neutralization.
    Komala Sari T; Gianopulos KA; Nicola AV
    J Virol; 2020 Feb; 94(5):. PubMed ID: 31826995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway.
    Hung SL; Peng C; Kostavasili I; Friedman HM; Lambris JD; Eisenberg RJ; Cohen GH
    Virology; 1994 Sep; 203(2):299-312. PubMed ID: 8053154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement.
    Nemerow GR; Jensen FC; Cooper NR
    J Clin Invest; 1982 Nov; 70(5):1081-91. PubMed ID: 6290536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes simplex virus type 1 evades the effects of antibody and complement in vivo.
    Lubinski JM; Jiang M; Hook L; Chang Y; Sarver C; Mastellos D; Lambris JD; Cohen GH; Eisenberg RJ; Friedman HM
    J Virol; 2002 Sep; 76(18):9232-41. PubMed ID: 12186907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC.
    Lubinski J; Wang L; Mastellos D; Sahu A; Lambris JD; Friedman HM
    J Exp Med; 1999 Dec; 190(11):1637-46. PubMed ID: 10587354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine.
    Awasthi S; Lubinski JM; Friedman HM
    Vaccine; 2009 Nov; 27(49):6845-53. PubMed ID: 19761834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herpes simplex virus glycoprotein C: molecular mimicry of complement regulatory proteins by a viral protein.
    Huemer HP; Wang Y; Garred P; Koistinen V; Oppermann S
    Immunology; 1993 Aug; 79(4):639-47. PubMed ID: 8406590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the role of glycoprotein C of HSV-1 and HSV-2 in viral binding may contribute to serotype differences in cell tropism.
    Gerber SI; Belval BJ; Herold BC
    Virology; 1995 Dec; 214(1):29-39. PubMed ID: 8525631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E.
    Hook LM; Huang J; Jiang M; Hodinka R; Friedman HM
    J Virol; 2008 Jul; 82(14):6935-41. PubMed ID: 18480440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic analysis of glycoprotein C of herpes simplex virus types 1 and 2 binding to heparin, heparan sulfate, and complement component C3b.
    Rux AH; Lou H; Lambris JD; Friedman HM; Eisenberg RJ; Cohen GH
    Virology; 2002 Mar; 294(2):324-32. PubMed ID: 12009874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune evasion by herpes simplex virus type 1, strategies for virus survival.
    Friedman HM
    Trans Am Clin Climatol Assoc; 2003; 114():103-12. PubMed ID: 12813914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cloning and expression of the complement receptor glycoprotein C from Herpesvirus simiae (herpes B virus): protection from complement-mediated cell lysis.
    Huemer HP; Wechselberger C; Bennett AM; Falke D; Harrington L
    J Gen Virol; 2003 May; 84(Pt 5):1091-1100. PubMed ID: 12692273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replication-Competent Controlled Herpes Simplex Virus.
    Bloom DC; Feller J; McAnany P; Vilaboa N; Voellmy R
    J Virol; 2015 Oct; 89(20):10668-79. PubMed ID: 26269179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade.
    Fries LF; Friedman HM; Cohen GH; Eisenberg RJ; Hammer CH; Frank MM
    J Immunol; 1986 Sep; 137(5):1636-41. PubMed ID: 3018078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific.
    Cairns TM; Huang ZY; Gallagher JR; Lin Y; Lou H; Whitbeck JC; Wald A; Cohen GH; Eisenberg RJ
    J Virol; 2015 Sep; 89(18):9213-31. PubMed ID: 26109729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative pathway of complement activation has a beneficial role against Chandipura virus infection.
    Gupta P; Tripathy AS
    Med Microbiol Immunol; 2020 Apr; 209(2):109-124. PubMed ID: 31781935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.